COVID-19 Resource Center

COVID-19 Resource Center

Source: Press Release


Disclosures: Harmon reports no relevant financial disclosures.
August 04, 2021
1 min read
Save

AMA releases provisional CPT code for potential third dose of Pfizer COVID-19 vaccine

Source: Press Release


Disclosures: Harmon reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The AMA has announced the CPT codes for a third dose of the Pfizer-BioNTech COVID-19 vaccine if one is authorized or approved by the FDA.

Last week, Pfizer disclosed data, which have not been peer-reviewed, that indicated a booster dose of its COVID-19 vaccine provides added protection beyond the currently recommended two doses, including against the delta variant.

Source: Adobe Stock.
The AMA released the CPT codes for a third dose of the Pfizer COVID-19 vaccine.
Photo source: Adobe Stock.

According to an AMA press release, the vaccine administration CPT code and long descriptor assigned to the third dose of the Pfizer COVID-19 vaccine is: “0003A immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose.”

Short, medium and long descriptors for the third dose and all other FDA-authorized COVID-19 vaccines can be found on AMA’s website, according to the organization.

The AMA said it is releasing the provisional code now to give health systems time to prepare for possible FDA authorization or approval of the third vaccine dose.

Gerald Harmon

“The FDA and CDC have analyzed data indicating that at this time individuals do not need to exceed the standard two doses authorized for Pfizer’s COVID-19 vaccine,” AMA President Gerald Harmon, MD, said in a press release. “The AMA supports the position of the CDC and FDA since it is based on a careful consideration of the available evidence to date. We are confident that federal health agencies will continue to review emerging evidence on a potential third dose of the Pfizer vaccine.”